Cargando…

Glitazone use associated with reduced risk of Parkinson's disease

BACKGROUND: Whether antidiabetic glitazone drugs protect against Parkinson's disease remains controversial. Although a single clinical trial showed no evidence of disease modulation, retrospective studies suggest that a disease‐preventing effect may be plausible. The objective of this study was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brakedal, Brage, Flønes, Irene, Reiter, Simone F., Torkildsen, Øivind, Dölle, Christian, Assmus, Jörg, Haugarvoll, Kristoffer, Tzoulis, Charalampos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697685/ https://www.ncbi.nlm.nih.gov/pubmed/28861893 http://dx.doi.org/10.1002/mds.27128

Ejemplares similares

A nationwide study of the incidence, prevalence and mortality of Parkinson’s disease in the Norwegian population
por: Brakedal, Brage, et al.
Publicado: (2022)

Nicotinamide riboside supplementation is not associated with altered methylation homeostasis in Parkinson’s disease
por: Gaare, Johannes J., et al.
Publicado: (2023)

NSAID use is not associated with Parkinson’s disease incidence: A Norwegian Prescription Database study
por: Brakedal, Brage, et al.
Publicado: (2021)

Defective mitochondrial DNA homeostasis in the substantia nigra in Parkinson disease
por: Dölle, Christian, et al.
Publicado: (2016)

Mitochondrial Respiratory Chain Dysfunction—A Hallmark Pathology of Idiopathic Parkinson’s Disease?
por: Flønes, Irene H., et al.
Publicado: (2022)

Novel SLC19A3 Promoter Deletion and Allelic Silencing in Biotin-Thiamine-Responsive Basal Ganglia Encephalopathy
por: Flønes, Irene, et al.
Publicado: (2016)

Genome-wide histone acetylation analysis reveals altered transcriptional regulation in the Parkinson’s disease brain
por: Toker, Lilah, et al.
Publicado: (2021)

Meta-analysis of whole-exome sequencing data from two independent cohorts finds no evidence for rare variant enrichment in Parkinson disease associated loci
por: Gaare, Johannes Jernqvist, et al.
Publicado: (2020)

NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease
por: Berven, Haakon, et al.
Publicado: (2023)

Mitochondrial respiratory chain deficiency correlates with the severity of neuropathology in sporadic Creutzfeldt-Jakob disease
por: Flønes, Irene H., et al.
Publicado: (2020)

Common gene expression signatures in Parkinson’s disease are driven by changes in cell composition
por: Nido, Gonzalo S., et al.
Publicado: (2020)

Early Forms of α-Synuclein Pathology Are Associated with Neuronal Complex I Deficiency in the Substantia Nigra of Individuals with Parkinson’s Disease
por: Flønes, Irene Hana, et al.
Publicado: (2022)

No evidence for rare TRAP1 mutations influencing the risk of idiopathic Parkinson’s disease
por: Gaare, Johannes J, et al.
Publicado: (2018)

Rare genetic variation in mitochondrial pathways influences the risk for Parkinson's disease
por: Gaare, Johannes J., et al.
Publicado: (2018)

Glitazone Treatment Rescues Phenotypic Deficits in a Fly Model of Gaucher/Parkinson’s Disease
por: Shola-Dare, Oluwanifemi, et al.
Publicado: (2021)

Glitazone Treatment and Incidence of Parkinson’s Disease among People with Diabetes: A Retrospective Cohort Study
por: Brauer, Ruth, et al.
Publicado: (2015)

Poly-ADP-ribose assisted protein localization resolves that DJ-1, but not LRRK2 or α-synuclein, is localized to the mitochondrial matrix
por: Osuagwu, Nelson, et al.
Publicado: (2019)

Are the adverse effects of glitazones linked to induced testosterone deficiency?
por: Carruthers, M, et al.
Publicado: (2008)

Pleiotropic Effects of Glitazones: A Double Edge Sword?
por: Salomone, Salvatore
Publicado: (2011)

Differential transcript usage in the Parkinson’s disease brain
por: Dick, Fiona, et al.
Publicado: (2020)

3,3′-Diaminobenzidine staining interferes with PCR-based DNA analysis
por: Dölle, Christian, et al.
Publicado: (2018)

Type 2 diabetes drug glitazone may help lowering risk of dementia by 22%
por: Fareed, Areeba, et al.
Publicado: (2023)

Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: meta-analysis of published observational studies
por: Pladevall, Manel, et al.
Publicado: (2016)

MRI characterisation of adult onset alpha-methylacyl-coA racemase deficiency diagnosed by exome sequencing
por: Haugarvoll, Kristoffer, et al.
Publicado: (2013)

Effect of glitazones on the progression of coronary artery disease in type 2 diabetes patients
por: Wyatt, Jamison, et al.
Publicado: (2010)

Changes in Glitazone Use Among Office-Based Physicians in the U.S., 2003–2009
por: Cohen, Andrew, et al.
Publicado: (2010)

Cited4 is a sex‐biased mediator of the antidiabetic glitazone response in adipocyte progenitors
por: Bayindir‐Buchhalter, Irem, et al.
Publicado: (2018)

Ultra-deep whole genome bisulfite sequencing reveals a single methylation hotspot in human brain mitochondrial DNA
por: Guitton, Romain, et al.
Publicado: (2022)

Activation of Peroxisome Proliferator-Activated Receptor-Gamma by Glitazones Reduces the Expression and Release of Monocyte Chemoattractant Protein-1 in Human Mesothelial Cells
por: Sauter, Matthias, et al.
Publicado: (2012)

In vitro characterization of six STUB1 variants in spinocerebellar ataxia 16 reveals altered structural properties for the encoded CHIP proteins
por: Pakdaman, Yasaman, et al.
Publicado: (2017)

Comparative analysis of therapeutic efficiency and costs (experience in Bulgaria) of oral antidiabetic therapies based on glitazones and gliptins
por: Filipova, Elena Pavlova, et al.
Publicado: (2015)

The Glitazone Class of Drugs as Carbonic Anhydrase Inhibitors—A Spin-Off Discovery from Fragment Screening
por: Mueller, Sarah L., et al.
Publicado: (2021)

Design and Development of Novel Glitazones for Activation of PGC-1α Signaling Via PPAR-γ Agonism: A Promising Therapeutic Approach against Parkinson’s Disease
por: Prabhakaran, Prabitha, et al.
Publicado: (2023)

Serum markers of multiple sclerosis - a new approach
por: Torkildsen, Øivind
Publicado: (2021)

EEGIFT: Group Independent Component Analysis for Event-Related EEG Data
por: Eichele, Tom, et al.
Publicado: (2011)

Novel glitazones as PPARγ agonists: molecular design, synthesis, glucose uptake activity and 3D QSAR studies
por: Mandal, Subhankar P., et al.
Publicado: (2018)

Advances in PPARs Molecular Dynamics and Glitazones as a Repurposing Therapeutic Strategy through Mitochondrial Redox Dynamics against Neurodegeneration
por: Durai, Priya, et al.
Publicado: (2022)

Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study
por: Chan, Cheng-Wei, et al.
Publicado: (2018)

Altered transcriptome-proteome coupling indicates aberrant proteostasis in Parkinson’s disease
por: Dick, Fiona, et al.
Publicado: (2023)

Dietary Vitamin D3 Supplements Reduce Demyelination in the Cuprizone Model
por: Wergeland, Stig, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_9ldpsbne6l0iujmv1gk6pitnq7